Bastien JAMET

Dr. Bastien JAMET

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
BJBastien JAMET
Bastien JAMET
LMLudivine Morvan
Ludivine Morvan
CNCristina Nanni
Cristina Nanni
AMAnne-Victoire Michaud
Anne-Victoire Michaud
CBClément Bailly
Clément Bailly
TCThomas Carlier
Thomas Carlier

9 April 2019 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
BJBastien JAMET
Bastien JAMET
CBClément Bailly
Clément Bailly
TCThomas Carlier
Thomas Carlier
CTCyrille Touzeau
Cyrille Touzeau
CNCristina Nanni
Cristina Nanni
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
The interest of 18Fluoro-deoxyglucose (FDG) positron emission tomography (PET) imaging in the management of patients with multiple myeloma (MM) for the workup at diagnosis and for therapeutic evaluation has recently been demonstrated. FDG-PET is a powerful imaging tool for bone lesions detection at initial diagnosis with high sensitivity and specificity values. The independent pejorative prognostic value on progression-free survival (PFS) and overall survival (OS) of baseline PET-derived parameters (presence of extra-medullary disease (EMD), number of focal bone lesions (FLs), and maximum standardized uptake values [SUVmax]) has been reported in several large independent prospective studies. During therapeutic evaluation, FDG-PET is considered as the reference imaging technique, because it can be performed much earlier than MRI which lacks specificity. Persistence of significant FDG uptake after treatment, notably before maintenance therapy, is an independent pejorative prognostic factor, especially for patients with a complete biological response. So FDG-PET and medullary flow cytometry are complementary tools for detection of minimal residual disease before maintenance therapy. However, the definition of PET metabolic complete response should be standardized. In patients with smoldering multiple myeloma, the presence of at least one hyper-metabolic lytic lesions on FDG-PET may be considered as a criterion for initiating therapy. FDG-PET is also indicated for initial staging of a solitary plasmacytoma so as to not disregard other bone or extra-medullary localizations. Development of nuclear medicine offer new perspectives for MM imaging. Recent PET tracers are willing to overcome limitations of FDG. (11)C-Methionine, which uptake reflects the increased protein synthesis of malignant cells seems to correlate well with bone marrow infiltration. Lipid tracers, such as Choline or acetate, and some peptide tracers, such as (68) Ga-Pentixafor, that targets CXCR4 (chemokine receptor-4, which is often expressed with high density by myeloma cells), are other promising PET ligands. 18F-fludarabine and immuno-PET targeting CD138 and CD38 also showed promising results in preclinical models.

Verified
Journal Article
Open access
PDF file
CBClément Bailly
Clément Bailly
RLRodolphe Leforestier
Rodolphe Leforestier
BJBastien JAMET
Bastien JAMET
TCThomas Carlier
Thomas Carlier
MBMickael Bourgeois
Mickael Bourgeois
CBCaroline Bodet-Milin
Caroline Bodet-Milin
Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells in the bone marrow. MM results in diffuse or focal bone infiltration and extramedullary lesions. Over the past two decades, advances have been made with regard to the diagnosis, staging, treatment, and imaging of MM. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently recommended as the most effective imaging modalities at diagnostic. Yet, recent data from the literature suggest that positron emission tomography combined with computed tomography (PET/CT) using 18F-deoxyglucose (FDG) is a promising technique for initial staging and therapeutic monitoring in this pathology. This paper reviews the recent advances as well as the potential place of a more specific radiopharmaceutical in MM.

6 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AMAnne-Victoire Michaud-Robert
Anne-Victoire Michaud-Robert
Elena ZamagniElena Zamagni
Elena Zamagni
TCThomas Carlier
Thomas Carlier
CBClément Bailly
Clément Bailly
BJBastien JAMET
Bastien JAMET
CBCaroline Bodet-Milin
Caroline Bodet-Milin
Background: Multiple myeloma is a hematological neoplasm characterized by a clonal proliferation of malignant plasma cells in the bone marrow, and is associated with high morbidity and mortality and variable survival. Positron emission tomography combined with computed tomography using 18F-deoxyfluoroglucose (FDG-PET/CT) is a promising technique for initial staging of symptomatic multiple myeloma patients. The objective of this study was to assess the prognostic value of this technique at baseline in symptomatic multiple myeloma patients included in two large European prospective studies (French and Italian). Methods: We retrospectively performed a combined harmonized analysis of 227 newly diagnosed transplant eligible multiple myeloma patients from two separate phase III trials. All images were centrally reviewed and analyzed using visual criteria and maximal standardized uptake value. An ad-hoc approach (called modified Combat) was applied to harmonize the data and then remove the “country effect” in order to strengthen the reliability of the final conclusions. Results: Using a multivariate analysis including treatment arm, R-ISS score, presence of extra-medullary disease and bone SUVmax, only bone SUVmax (p = 0.016) was an independent prognosis factor with an OS threshold of 7.1. For PFS, treatment arm and presence of extra-medullary disease were both independent prognosis biomarkers (p = 0.022 and 0.006 respectively). Conclusions: Our results show that bone SUVmax is a simple and reliable biomarker to analyze FDG-PET/CT at baseline that strongly correlates with a poorer prognosis for MM patients.

Verified
Journal Article
Open access
PDF file
BJBastien JAMET
Bastien JAMET
Elena ZamagniElena Zamagni
Elena Zamagni
CNCRISTINA NANNI
CRISTINA NANNI
CBClément Bailly
Clément Bailly
TCThomas Carlier
Thomas Carlier
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
Serum markers and bone marrow examination are commonly used for monitoring therapy response in multiple myeloma (MM), but this fails to identify minimal residual disease (MRD), which frequently persists after therapy even in complete response patients, and extra-medullary disease escape. Positron emission tomography with computed tomography using 18F-deoxyglucose (FDG-PET/CT) is the reference imaging technique for therapeutic assessment and MRD detection in MM. To date, all large prospective cohort studies of transplant-eligible newly diagnosed MM patients have shown a strong and independent pejorative prognostic impact of not obtaining complete metabolic response by FDG-PET/CT after therapy, especially before maintenance. The FDG-PET/CT and MRD (evaluated by flow cytometry or next-generation sequencing at 10−5 and 10−6 levels, respectively) results are complementary for MRD detection outside and inside the bone marrow. For patients with at least a complete response, to reach double negativity (FDG-PET/CT and MRD) is a predictive surrogate for patient outcome. Homogenization of FDG-PET/CT interpretation after therapy, especially clarification of complete metabolic response definition, is currently underway. FDG-PET/CT does not allow MRD to be evaluated when it is negative at initial workup of symptomatic MM. New PET tracers such as CXCR4 ligands have shown high diagnostic value and could replace FDG in this setting. New sensitive functional magnetic resonance imaging (MRI) techniques such as diffusion-weighted MRI appear to be complementary to FDG-PET/CT for imaging MRD detection. The goal of this review is to examine the feasibility of functional imaging, especially FDG-PET/CT, for therapeutic assessment and MRD detection in MM.

18 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
BJBastien JAMET
Bastien JAMET
TCThomas Carlier
Thomas Carlier
Loic CampionLoic Campion
Loic Campion
EBEmmanuelle Bompas
Emmanuelle Bompas
SGSylvie Girault
Sylvie Girault
CRCaroline Rousseau
Caroline Rousseau
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Bastien Jamet1, Thomas Carlier2, 3, Loic Campion2, 4, Emmanuelle Bompas4, Sylvie Girault5, Fanny Borrely6, Ludovic Ferrer7, Maxime Rousseau1, Yann Venel6, Françoise Kraeber-Bodéré1, 2, 3 and Caroline Rousseau1, 2 1Nuclear Medicine Unit, ICO Cancer Center Gauducheau, Saint Herblain, France 2Nantes-Angers Cancer Research Center, INSERM U892, CNRS UMR 6299, University of Nantes, Nantes, France 3Nuclear Medicine Unit, University Hospital, Nantes, France 4Oncology Unit, ICO Cancer Center Gauducheau, Saint Herblain, France 5Nuclear Medicine Unit, ICO Cancer Center Papin, Angers, France 6Nuclear Medicine Unit, University Hospital Bretonneau, Tours, France 7Physics Unit, ICO Cancer Center Gauducheau, Saint Herblain, France Correspondence to: Jamet Bastien, email: bastien.jamet@chu-nantes.fr Keywords: FDG-PET/CT, oncology, ewing sarcoma family of tumors, survival analysis, prognosis Received: May 11, 2017 Accepted: June 27, 2017 Published: August 18, 2017 ABSTRACT Purpose: The aim of this retrospective study was to determine, at baseline, the prognostic value of different FDG-PET/CT quantitative parameters in a homogenous Ewing Sarcoma Family of Tumors (ESFT) adult population, compared with clinically relevant prognostic factors. Methods: Adult patients from 3 oncological centers, all with proved ESFT, were retrospectively included. Quantitative FDG-PET/CT parameters (SUV (maximum, peak and mean), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of the primary lesion of each patient were recorded before treatment, as well as usual clinical prognostic factors (stage of disease, location, tumor size, gender and age). Then, their relation with progression free survival (PFS) and overall survival (OS) was evaluated. Results: 32 patients were included. Median age was 21 years (range, 15 to 61). Nineteen patients (59%) were initially metastatic. On multivariate analysis, high SUVmax remained independent predictor of worst OS (p=0.02) and PFS (p=0.019), metastatic disease of worst PFS (p=0.01) and high SUVpeak of worst OS (p=0.01). Optimal prognostic cut-off of SUVpeak was found at 12.5 in multivariate analyses for PFS and OS (p=0.0001). Conclusions: FDG-PET/CT, recommended at ESFT diagnosis for initial staging, can be a useful tool for predicting long-term adult patients outcome through semi-quantitative parameters.